ICUD-EAU international consultation on kidney cancer 2010: Treatment of metastatic disease Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Brain Neoplasms
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Lung Neoplasms
  • Pancreatic Neoplasms

abstract

  • Increasing clinical evidence is clarifying appropriate first- and second-line treatments with targeted agents for patients with mRCC. Based on phase 2 and 3 trials, a sequential approach is most promising, while combination therapy is still investigational. The role of nephrectomy in mRCC is being evaluated in ongoing phase 3 clinical trials.

publication date

  • October 2011

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2011.06.017

PubMed ID

  • 21704448

Additional Document Info

start page

  • 684

end page

  • 90

volume

  • 60

number

  • 4